1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Gastroenteritis-Pipeline Insights, 2017

Gastroenteritis-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Gastroenteritis-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Gastroenteritis. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Gastroenteritis. DelveInsight’s Report also assesses the Gastroenteritis therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Gastroenteritis
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Gastroenteritis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Gastroenteritis and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Gastroenteritis-Pipeline Insights, 2017
Illustrative

- Gastroenteritis Overview
- Gastroenteritis Pipeline Therapeutics
- Gastroenteritis Therapeutics under Development by Companies
- Gastroenteritis Filed and Phase III Products
- Comparative Analysis
- Gastroenteritis Phase II Products
- Comparative Analysis
- Gastroenteritis Phase I and IND Filed Products
- Comparative Analysis
- Gastroenteritis Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Gastroenteritis - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastroenteritis - Discontinued Products
- Gastroenteritis - Dormant Products
- Companies Involved in Therapeutics Development for Gastroenteritis
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Gastroenteritis, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Gastroenteritis Assessment by Monotherapy Products
- Gastroenteritis Assessment by Combination Products
- Gastroenteritis Assessment by Route of Administration
- Gastroenteritis Assessment by Stage and Route of Administration
- Gastroenteritis Assessment by Molecule Type
- Gastroenteritis Assessment by Stage and Molecule Type
- Gastroenteritis Therapeutics - Discontinued Products
- Gastroenteritis Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Gastroenteritis, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Gastroenteritis Assessment by Monotherapy Products
- Gastroenteritis Assessment by Combination Products
- Gastroenteritis Assessment by Route of Administration
- Gastroenteritis Assessment by Stage and Route of Administration
- Gastroenteritis Assessment by Molecule Type
- Gastroenteritis Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Non-alcoholic Steatohepatitis Biomarkers Market and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Non-alcoholic Steatohepatitis Biomarkers Market and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Non-alcoholic Steatohepatitis Biomarker Market: Overview Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). ...

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global human microbiome market is estimated to reach USD 899.1 million by 2025, growing at a CAGR of 21.1% during the forecast period (2022–2025) Factors such as increased focus on human microbiome ...

Epiomic Epidemiology Series: Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Irritable Bowel Syndrome Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Irritable Bowel Syndrome in 12 Major Markets Irritable Bowel Syndrome (IBS) is a functional bowel disorder which incorporates a group ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.